General Information of Drug (ID: DMPVW2Q)

Drug Name
PMID30280939-Compound-US20179642901 Drug Info
Indication
Disease Entry ICD 11 Status REF
Malaria 1F40-1F45 Patented [1]
Cross-matching ID
TTD Drug ID
DMPVW2Q

Molecule-Related Drug Atlas

Molecule-Related Drug Atlas
Molecule Type:
DTT
Drug Status:
Clinical Trial Drug(s)
Patented Agent(s)
Drug(s) Targeting Toll-like receptor (TLR)
Drug Name Drug ID Indication ICD 11 Highest Status REF
DPV-001 DMMC3XR Non-small-cell lung cancer 2C25.Y Phase 2 [2]
BDB001 DMKFJXP Solid tumour/cancer 2A00-2F9Z Phase 2 [3]
IMO-8400 DMDPNCJ Rheumatoid arthritis FA20 Phase 2 [4]
IMO-9200 DMEHWPC Autoimmune disease 4A40-4A45 Phase 1 [5]
PMID30280939-Compound-WO2009082440 DMXRHCJ N. A. N. A. Patented [1]
PMID30280939-Compound-WO2015150568 DMGCE3Z N. A. N. A. Patented [1]
PMID30280939-Compound-WO200606195 DMLVSEK N. A. N. A. Patented [1]
PMID30280939-Compound-WO2005070959 DM6VP5K N. A. N. A. Patented [1]
PMID30280939-Compound-WO2013148426 DMUKIEJ Malaria 1F40-1F45 Patented [1]
PMID30280939-Compound-WO2013148427 DM4Z2KY N. A. N. A. Patented [1]
⏷ Show the Full List of 10 Drug(s)

Molecular Interaction Atlas of This Drug

Molecular Interaction Atlas

Drug Therapeutic Target (DTT)
DTT Name DTT ID UniProt ID MOA REF
Toll-like receptor (TLR) TTOK0LR NOUNIPROTAC Agonist [1]

References

1 Synthetic Toll-like receptor agonists for the development of powerful malaria vaccines: a patent review.Expert Opin Ther Pat. 2018 Nov;28(11):837-847.
2 UbiVac's DRibble, autophagosome-enriched vaccines: Applications for cancer and infectious disease. UbiVac. 2013.
3 Clinical pipeline report, company report or official report of the Pharmaceutical Research and Manufacturers of America (PhRMA)
4 Clinical pipeline report, company report or official report of the Pharmaceutical Research and Manufacturers of America (PhRMA)
5 Clinical pipeline report, company report or official report of the Pharmaceutical Research and Manufacturers of America (PhRMA)